Ọgwụgwọ CAR-T maka Ọrịa Kansa Afọ

Claudin18.2 (CLDN18.2) bụ ụdị protein dị n'etiti nke a na-egosipụta kpọmkwem na epithelium afọ ma na-egosipụta oke oke n'elu mkpụrụ ndụ kansa afọ. CT041 (koodu mmepe CG4006) bụ ngwaahịa CAR-T nke na-elekwasị anya na CLDN18.2. Data nke Usoro nke Mbụ na-egosi ọrụ mgbochi etuto ahụ na-ekwe nkwa na ndị ọrịa kansa afọ nke a na-agwọbeghị nke ọma, ndị nwere CLDN18.2 nwere ọrịa kansa afọ.

A na-ahụkwa oke mmụba nke HER2 n'ime otu ndị ọrịa kansa afọ. Ọgwụgwọ CAR-T nke HER2 lekwasịrị anya egosila na ọ nwere ike igbochi etuto ahụ n'ọmụmụ ihe gbasara ahụike tupu ọgwụgwọ na mmalite. TAC01-HER2 nke Triumvira Immunologics nọ ugbu a na nnwale ahụike nke Usoro nke Abụọ.

• Nzube Pụrụ Iche nke Pụrụ Iche: Site n'iduzi mkpụrụ ndụ CAR-T megide CLDN18.2 ma ọ bụ HER2, enwere ike ịchọpụta ma wepụ mkpụrụ ndụ kansa afọ nke ọma, na-ebelata mmetụta ndị na-abụghị etuto ahụ.

• Imeri Mgbochi Ọgwụgwọ Ọtụtụ AhịrịN'ime nnwale CT041, otu ndị ọrịa kansa afọ nwetara ọnụego nzaghachi ebumnuche (ORR) nke 57.1%, ọnụego njikwa ọrịa (DCR) nke 75.0%, na ndụ ọnwa isii (OS) nke 81.2% n'ime ndị ọrịa dara ọtụtụ usoro ọgwụgwọ gara aga.

• Nzaghachi Ndị Na-adịgide AdịgideỌgwụgwọ CLDN18.2-CAR-T nyere oge nzaghachi nke ọnwa isii nke 44.8%, nke na-egosi na ọ ga-abara uru ogologo oge n'ụlọ ọgwụ.

• Ọgwụgwọ nkeonwe: Iji mkpụrụ ndụ T nke onye ọrịa ahụ na-ebelata ohere nke ịjụ ya ma na-eme ka nchekwa na irè ya ka mma.

• Nchịkọta T-Cell Ọbara nke dị n'akụkụ
  A na-ewepụ mkpụrụ ndụ T n'ọbara onye ọrịa site na leukapheresis.

• Injinịa Mkpụrụ Ndụ Ihe Nketa
  N'ime ụlọ nyocha nke GMP kwadoro, a na-agbanwe mkpụrụ ndụ T ka ha gosipụta CAR nke na-elekwasị anya na CLDN18.2 ma ọ bụ HER2, wee gbasaa ex vivo.

• Ọnọdụ Lymphodepleting
  A na-enye usoro nkwadebe nke cyclophosphamide na fludarabine iji belata lymphocytes dị n'ime ahụ ma mepụta ebe dị mma maka mgbasawanye nke mkpụrụ ndụ CAR-T.

• Ntinye mkpụrụ ndụ CAR-T
  A na-etinye mkpụrụ ndụ CAR-T ndị e mebere eme n'ime onye ọrịa ahụ n'ime akwara.

• Nlekota na Njikwa
  Mgbe a mịnyechara ya ọgwụ ahụ, a na-enyocha ndị ọrịa nke ọma maka ọrịa cytokine release syndrome (CRS) na nsogbu akwara ozi, a na-enyekwa aka n'oge dịka ọ dị mkpa.

• Nyocha Oge nke CT041 (CLDN18.2-CAR-T) nke Oge Mbụ
  N'ime ndị ọrịa iri atọ na asaa a gwọrọ nke ukwuu, otu ndị na-arịa ọrịa kansa afọ ruru ORR 57.1%, DCR 75.0%; 94.6% nwetara naanị CRS nke ọkwa 1-2, na-enweghị CRS nke ọkwa 3 ma ọ bụ karịa ma ọ bụ nsí akwara; oge ọnwa isii nke nzaghachi bụ 44.8%.

• Nsonaazụ ikpeazụ nke usoro nke mbụ nke Satri-cel (nke na-elekwasịkwa anya na CLDN18.2)
  N'ime mmadụ 98 nwere ọrịa kansa afọ nke nwere CLDN18.2, ORR bụ 38.8%, DCR 91.8%; ndụ nke na-enweghị ọganihu (mPFS) bụ ọnwa 4.4 (95% CI 3.7–6.6), ndụ nke na-enweghị ọganihu (mOS) bụ ọnwa 8.8 (95% CI 7.1–10.2); 96.9% nwetara naanị CRS nke Klas 1–2, na-enweghị CRS nke Klas 3+ ma ọ bụ ọnwụ ndị metụtara ya.

• Nkọwa Ọgwụ Mmalite nke HER2-CAR-T
  Ọmụmụ ihe nke mbụ nke Usoro Mbụ n'ime mmadụ gosiri na ọ dị mfe ijikwa nchekwa; a na-aga n'ihu na nnwale ndebanye aha nke Usoro nke Abụọ.

• Ikpo Okwu Teknụzụ Ndị Na-eduga
  BIOOCUS na-arụ ọrụ n'ụlọ ọrụ mmepụta ọgwụgwọ mkpụrụ ndụ nke ọkwa GMP zuru ụwa ọnụ, na-ahụ na mmepụta mkpụrụ ndụ CAR-T dị irè ma na-agbanwe agbanwe.

• Ndị otu ọkachamara dị iche iche
  Ndị otu anyị gụnyere ndị ọkachamara nwere ahụmahụ na immunology, oncology, na ọgwụgwọ mkpụrụ ndụ, na-enye njikwa zuru oke nkeonwe.

• Ahụmịhe Ahụike Mba Nile
  Anyị agwọọla ndị ọrịa sitere n'akụkụ ụwa niile, na-anakọta ọtụtụ data nchekwa na arụmọrụ.

• Ọrụ zuru oke site na njedebe ruo na njedebe
  Site na nhazi usoro na nhazi ọgwụgwọ mba ofesi ruo na nleba anya ogologo oge mgbe a gwọchara ya, BIOOCUS na-enye nkwado otu nkwụsị.